Expression of 14-3-3σ in cervical squamous cell carcinomas: Relationship with clinical outcome

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 11-15

  Holm, Ruth ^a   Ali, Tayeba ^a   Svendsrud, Debbie H ^b   Nesland, Jahn M ^a   Kristensen, Gunnar B ^a   Lyng, Heidi ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b INSTITUTE OF CANCER RESEARCH   (Norway)

Author keywords

14 3 3 ; Cervical squamous cell carcinomas; Immuno histochemistry

Indexed keywords

MESSENGER RNA; STRATIFIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ACTIVE TRANSPORT, CELL NUCLEUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; DISEASE-FREE SURVIVAL; EXONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 68249160101     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000399     Document Type: Article

References (33)

1. Globocan 2000: Cancer incidence, mortality and prevalence worldwide. In: IARC Cancer Base No. 5 (Version 1.0). IARCPress, Lyon, 2001.
2. Gasinska A, Urbanski K, Adamczyk A, Pudelek J, Lind BK and Brahme A: Prognostic significance of intratumour microvessel density and haemoglobin level in carcinoma of the uterine cervix. Acta Oncol 41: 437-443, 2002.
3. Van Bommel PF, van Lindert AC, Kock HC, Leers WH and Neijt JP: A review of prognostic factors in early-stage carcinoma of the cervix (FIGO I B and II A) and implications for treatment strategy. Eur J Obstet Gynecol Reprod Biol 26: 69-84, 1987.
4. Kawagoe T, Kashimura M, Matsuura Y, Sugihara K, Toki N and Aoki T: Clinical significance of tumor size in stage IB and II carcinoma of the uterine cervix. Int J Gynecol Cancer 9: 421-426, 1999.
5. Waggoner SE: Cervical cancer. Lancet 361: 2217-2225, 2003.
6. Creasman WT and Kohler MF: Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol Oncol 92: 525-529, 2004.
7. Rutledge FN, Mitchell MF, Munsell M, Bass S, McGuffee V and Atkinson EN: Youth as a prognostic factor in carcinoma of the cervix: a matched analysis. Gynecol Oncol 44: 123-130, 1992.
8. Muslin AJ, Tanner JW, Allen PM and Shaw AS: Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84: 889-897, 1996.
9. Mhawech P: 14-3-3 proteins - an update. Cell Res 15: 228-236, 2005.
10. Prasad GL, Valverius EM, McDuffie E and Cooper HL: Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 3: 507-513, 1992.
11. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
12. Laronga C, Yang HY, Neal C and Lee MH: Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275: 23106-23112, 2000.
13. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N and Dahiya R: Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316: 1156-1162, 2004.
14. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, Nitta M, Okamura H, Inoue S, Sasano H, Okamura K and Yaegashi N: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 10: 2687-2693, 2004.
15. Mhawech P, Greloz V, Assaly M and Herrmann F: Immunohistochemical expression of 14-3-3 sigma protein in human urological and gynecological tumors using a multi-tumor microarray analysis. Pathol Int 55: 77-82, 2005.
16. Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B, Gusterson B, Evans DJ and Crook T: Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene 21: 1876-1881, 2002.
17. Wang Z, Trope CG, Suo Z, Troen G, Yang G, Nesland JM and Holm R: The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas. BMC Cancer 8: 308, 2008.
18. Ito K, Suzuki T, Akahira J, Sakuma M, Saitou S, Okamoto S, Niikura H, Okamura K, Yaegashi N, Sasano H and Inoue S: 14-3-3sigma in endometrial cancer - a possible prognostic marker in early-stage cancer. Clin Cancer Res 11: 7384-7391, 2005.
19. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E, Takada M and Takahashi T: Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 21: 2418-2424, 2002.
20. Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, Yulug I, Numico G, Merlano M, Farrell PJ, Tavassoli M, Gusterson B and Crook T: Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 62: 2072-2076, 2002.
21. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, Satoh T, Toyota J, Satoh M, Endo T and Imai K: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19: 5298-5302, 2000.
22. Lodygin D, Yazdi AS, Sander CA, Herzinger T and Hermeking H: Analysis of 14-3-3sigma expression in hyper-proliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 22: 5519-5524, 2003.
23. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR and Sukumar S: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97: 6049-6054, 2000.
24. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Steele D, Cossu A, Budroni M, Palmieri G and Lakhani SR: Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol 202: 274-285, 2004.
25. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H and Imai K: Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000.
26. Tanaka K, Hatada T, Kobayashi M, Mohri Y, Tonouchi H, Miki C, Nobori T and Kusunoki M: The clinical implication of 14-3-3 sigma expression in primary gastrointestinal malignancy. Int J Oncol 25: 1591-1597, 2004.
27. Mhawech P, Benz A, Cerato C, Greloz V, Assaly M, Desmond JC, Koeffler HP, Lodygin D, Hermeking H, Herrmann F and Schwaller J: Down-regulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 18: 340-348, 2005.
28. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R and Amberger A: 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11: 3274-3279, 2005.
29. Lyng H, Brovig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfor K, Kristensen GB and Stokke T: Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 7: 268, 2006.
30. Sano T, Shimooka H, Weixa P, Segawa A, Jian Z, Motegi A, Nakayama H, Oyama T and Nakajima T: Immunohistochemical expression of 14-3-3 sigma protein in various histological sub-types of uterine cervical cancers. Pathol Int 54: 743-750, 2004.
31. Van Hemert MJ, Niemantsverdriet M, Schmidt T, Backendorf C and Spaink HP: Isoform-specific differences in rapid nucleocytoplasmic shuttling cause distinct subcellular distributions of 14-3-3 sigma and 14-3-3 zeta. J Cell Sci 117: 1411-1420, 2004.
32. Audic Y and Hartley RS: Post-transcriptional regulation in cancer. Biol Cell 96: 479-498, 2004.
33. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y and Inoue S: Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417: 871-875, 2002. ONCOLOGY REPORTS 22: 11-15, 2009 15